Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01969708
Other study ID # SCORE2
Secondary ID U10EY023529U10EY
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2014
Est. completion date March 2021

Study information

Verified date June 2021
Source The Emmes Company, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.


Description:

The primary objective of SCORE2 is to test for non-inferiority based on mean change from baseline in visual acuity letter score at Month 6 for eyes randomized to intravitreal bevacizumab every 4 weeks compared with eyes randomized to intravitreal aflibercept every 4 weeks using a non-inferiority margin of 5 letters. Secondary objectives of SCORE2 are to: - compare the bevacizumab and the aflibercept groups with regards to central retinal thickness, as measured with spectral domain optical coherence tomography (SD-OCT), at Month 6 and change between baseline and Month 6; - assess Month 12 visual acuity and SD-OCT outcomes associated with different dosing strategies after Month 6 in participants who respond well to treatment; - assess Month 12 visual acuity and SD-OCT outcomes associated with alternative treatment strategies after Month 6 in participants who respond poorly to treatment; - compare area of retinal ischemia and rates of neovascular complications of CRVO in the bevacizumab vs. aflibercept groups; - add to our knowledge of the safety profile of these anti-vascular endothelial growth factor (VEGF) medications in the setting of eyes with macular edema secondary to CRVO; - conduct a cost effectiveness analysis comparing intravitreal bevacizumab to intravitreal aflibercept to assess the economic implications from a payor perspective using decision analytic methods. Other exploratory aims of SCORE2 are to: - investigate the correlation of features identified through SD-OCT segmentation analysis, such as the inner segment-outer segment (IS-OS) junction (also known as the ellipsoid zone), with such characteristics as visual acuity and central retinal thickness; - investigate the correlation of area of peripheral retinal nonperfusion from widefield fluorescein angiography with visual acuity and central retinal thickness, and the prognostic value of baseline peripheral and central retina perfusion status in predicting disease course and treatment responsiveness; - investigate the correlation of features on adaptive optics imaging with such characteristics as visual acuity and central retinal thickness.


Recruitment information / eligibility

Status Completed
Enrollment 362
Est. completion date March 2021
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must have center-involved macular edema secondary to CRVO. Eyes may be enrolled as early as the time of diagnosis of the macular edema. The definition of CRVO used in SCORE will also be used for the purposes of SCORE2: a CRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in all 4 quadrants. - Due to the similarities of a hemiretinal vein occlusion (HRVO) to CRVO,HRVO will be classified as CRVO for the purposes of this clinical trial. Eyes classified as having a HRVO will be limited to no more than 25% of the planned sample size. A HRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g. telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in 5 or more clock hours but less than all 4 quadrants. Typically, a HRVO is a retinal vein occlusion that involves 2 altitudinal quadrants. - E-Early Treatment Diabetic Retinopathy Study (ETDRS)visual acuity score of greater than or equal to 19 letters (approximately 20/400) and less than or equal to 73 letters (approximately 20/40) by the ETDRS visual acuity protocol. The investigator must believe that a study eye with visual acuity between 19 and 33 letters is perfused. - Retinal thickness on SD-OCT measurement, defined as central subfield thickness of 300 µm or greater. If the SD-OCT measurement is taken from a Heidelberg Spectralis Machine, the central subfield thickness should be 320 µm or greater. - Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs. Exclusion Criteria: - A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers indicating difficulty in long term follow-up, likelihood of survival of less than 12 months). - Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at time of study entry. - History of allergy to any anti-VEGF agent, corticosteroid, or component of the delivery vehicle. - The participant will be moving out of the area of the clinical site to an area not covered by another clinical site during the 12 months of the study. - Positive urine pregnancy test: all women of childbearing potential (those who are pre-menopausal and not surgically sterilized) may participate only if they have a negative urine pregnancy test, and if they do not intend to become pregnant during the timeframe of the study. Women who are sexually active with a male partner must agree to use at least one of the following birth control methods: hormonal therapy such as oral, implantable or injectable chemical contraceptives; mechanical therapy such as spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. - Women who are breast-feeding. - Examination evidence of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT thought to be contributing to macular edema. - An eye that, in the investigator's opinion, would not benefit from resolution of macular edema such as eyes with foveal atrophy, dense pigmentary changes or dense subfoveal hard exudates. - Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, iris neovascularization, Irvine-Gass Syndrome, prior macula-off rhegmatogenous retinal detachment). - Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract). - History of laser photocoagulation for macular edema within 3 months prior to randomization. - History of intravitreal corticosteroid within 4 months of randomization. - Intravitreal anti-VEGF injection within 2 months of randomization. Note: Enrollment will be limited to no more than 25% of the planned sample size with any history of anti-VEGF treatment. Once this number of eyes has been enrolled, any history of anti-VEGF treatment will be an exclusion criterion. For enrollment of study eyes with prior intravitreal anti-VEGF agents, in the opinion of the investigator, the treatment response to prior anti-VEGF treatment must be either incomplete or the study eye had developed recurrent CRVO-associated macular edema, such that the study eye would benefit from additional anti-VEGF treatment. - History of peribulbar or retrobulbar corticosteroid use for any reason within 2 months prior to randomization. - History of panretinal scatter photocoagulation (PRP) or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 3 months following randomization. - History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within 4 months prior to randomization or anticipated within the next 6 months following randomization. - History of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization. - Aphakia. - Presence of an anterior chamber intraocular lens - Examination evidence of external ocular infection, including conjunctivitis, chalazion or significant blepharitis. - History of macular detachment. - Examination evidence of any diabetic retinopathy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
aflibercept

bevacizumab


Locations

Country Name City State
United States Retina Research Institute of Texas Abilene Texas
United States Texas Retina Associates Arlington Texas
United States Emory University Eye Center Atlanta Georgia
United States Southeast Retina Center Augusta Georgia
United States The Retina Research Center Austin Texas
United States Elman Retina Group, PA Baltimore Maryland
United States Charlotte Eye Ear Nose & Throat Associates, P.A. Charlotte North Carolina
United States The Retina Group of Washington Chevy Chase Maryland
United States Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology Chicago Illinois
United States Retina Associates of Cleveland, Inc. Cleveland Ohio
United States The Ohio State University Columbus Ohio
United States Texas Retina Associates Dallas Texas
United States Henry Ford Health System Detroit Michigan
United States The Retina Group of Washington Fairfax Virginia
United States Carolinas Centers for Sight, PC Florence South Carolina
United States Retina Group of Florida Fort Lauderdale Florida
United States National Ophthalmic Research Institute Fort Myers Florida
United States Elman Retina Group, P.A. Glen Burnie Maryland
United States Cumberland Valley Retina Consultants Hagerstown Maryland
United States Charlotte Eye Ear Nose & Throat Associates, P.A. Houston Texas
United States Retina & Vitreous of Texas Houston Texas
United States Retina Consultants of Houston, PA Houston Texas
United States Thomas A. Ciulla, MD, PC Indianapolis Indiana
United States TLC Eyecare & Laser Centers Jackson Michigan
United States University of Florida, Dept of Ophthalmology Jacksonville Florida
United States Southeastern Retina Associates, PC Knoxville Tennessee
United States Florida Retina Consultants Lakeland Florida
United States Retina Consultants of Nevada Las Vegas Nevada
United States Delaware Valley Retina Associates Lawrenceville New Jersey
United States Sabates Eye Centers Leawood Kansas
United States Retina Associates of Kentucky Lexington Kentucky
United States University of Kentucky Lexington Kentucky
United States University of Wisconsin Madison Wisconsin
United States Georgia Retina, P.C. Marietta Georgia
United States Valley Retina Institute, PA McAllen Texas
United States Medical College of Wisconsin Milwaukee Wisconsin
United States VitreoRetinal Surgery Minneapolis Minnesota
United States Retina Vitreous Consultants Monroeville Pennsylvania
United States Northern California Retina Vitreous Associates Mountain View California
United States Tennessee Retina, PC Nashville Tennessee
United States Vanderbilt Eye Institute Nashville Tennessee
United States NJ Retina New Brunswick New Jersey
United States New England Retina Associates New London Connecticut
United States New York Eye and Ear Infirmary New York New York
United States East Bay Retina Consultants, Inc. Oakland California
United States Dean McGee Eye Institute Oklahoma City Oklahoma
United States UNMC Truhlsen Eye Institute Omaha Nebraska
United States Paducah Retinal Center Paducah Kentucky
United States Southern California Desert Retina Consultants Palm Desert California
United States Scheie Eye Institute Philadelphia Pennsylvania
United States Retinal Consultants of AZ Phoenix Arizona
United States Elman Retina Group, P.A. Pikesville Maryland
United States Casey Eye Institute / OHSU Portland Oregon
United States Retina Northwest, PC Portland Oregon
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Mayo Clinic Rochester Minnesota
United States Retina Associates of Western New York Rochester New York
United States University of Rochester Flaum Eye Institute Rochester New York
United States Retinal Consultants Medical Group, Inc. Sacramento California
United States University of California Davis, Medical Center Sacramento California
United States The Retina Institute Saint Louis Missouri
United States Medical Center Ophthalmology Associates San Antonio Texas
United States Retinal Consultants of San Antonio San Antonio Texas
United States University of California, San Francisco San Francisco California
United States Sarasota Retina Institute Sarasota Florida
United States Retina Associates, PA Shawnee Mission Kansas
United States Charlotte Eye Ear Nose & Throat Associates, P.A. Statesville North Carolina
United States Retina Vitreous Surgeon of CNY, PC Syracuse New York
United States Retina Centers, P.C. Tucson Arizona
United States Palmetto Retina Center West Columbia South Carolina
United States Center for Retina and Macular Disease Winter Haven Florida
United States Florida Retina Consultants Winter Haven Florida

Sponsors (4)

Lead Sponsor Collaborator
The Emmes Company, LLC Milton S. Hershey Medical Center, National Eye Institute (NEI), University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

References & Publications (12)

Etheridge T, Blodi B, Oden N, Van Veldhuisen P, Scott IU, Ip MS, Mititelu M, Domalpally A. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15. Ophthalmol Retina. 2020 Dec 26. pii: S2468-6530(20)30503-0. doi: 10.1016/j.oret.2020.12.016. [Epub ahead of print] — View Citation

Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14. Transl Vis Sci Technol. 2021 Mar 1;10(3):31. doi: 10.1167/tvst.10.3.31. — View Citation

Etheridge T, Dobson ETA, Wiedenmann M, Papudesu C, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study. PLoS One. 2020 Apr 30;15(4):e0232494. doi: 10.1371/journal.pone.0232494. eCollection 2020. — View Citation

Hendrick A, VanVeldhuisen PC, Scott IU, King J, Blodi BA, Ip MS, Khurana RN, Oden NL; SCORE2 Investigator Group. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials. Am J Ophthalmol. 2021 Feb;222:185-193. doi: 10.1016/j.ajo.2020.08.030. Epub 2020 Aug 20. — View Citation

Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. JAMA Ophthalmol. 2019 Mar 1;137(3):281-287. doi: 10.1001/jamaophthalmol.2018.6111. — View Citation

Peterson JS, Rockwell K Jr, Scott IU, Ip MS, VanVeldhuisen PC, Blodi BA; SCORE2 Investigator Group. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS. Retina. 2019 Sep;39(9):1802-1809. doi: 10.1097/IAE.0000000000002212. — View Citation

Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE2 Investigator Group. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2017 Dec;184:147-156. doi: 10.1016/j.ajo.2017.10.008. Epub 2017 Oct 23. — View Citation

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM; SCORE2 Investigator Group. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Apr 1;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843. — View Citation

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occ — View Citation

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group. SCORE2 Report 2: Study Design and Baseline Characteristics. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub 2016 Nov 15. — View Citation

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M; SCORE2 Investigator Group. SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion. Am J Ophthalmol. 2016 Oct;170:25-31. doi: 10.1016/j.ajo.2016.07.011. Epub 2016 Jul 19. — View Citation

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M; SCORE2 Investigator Group. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. Month 0 to 6
Secondary Number of Study Eyes With Gain of =15 Letters in Visual Acuity Letter Score at Month 6 The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6 Month 0 to 6
Secondary Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6 The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6 Month 0 to 6
Secondary Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography Month 0 to 6
Secondary Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6 The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness Month 0 to 6
Secondary Number of Study Eyes With Central Subfield Thickness <300 µm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces The measure is the number of study eyes with central subfield thickness <300 µm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6 Month 0 to 6
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Completed NCT03981549 - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Phase 1/Phase 2
Completed NCT02274259 - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Phase 4
Completed NCT01360385 - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab N/A
Not yet recruiting NCT00383773 - Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion N/A
Completed NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion N/A
Recruiting NCT04601701 - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Withdrawn NCT03417401 - Surgical Stabilizer Assisted RVC With rtPA for CRVO Phase 1
Completed NCT01976312 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Phase 3
Completed NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Phase 1/Phase 2
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Active, not recruiting NCT01011374 - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion Phase 1
Completed NCT03223714 - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Phase 3
Recruiting NCT01827722 - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Phase 4
Completed NCT00906685 - Bevacizumab for Central Retinal Vein Occlusion Study Phase 3
Active, not recruiting NCT04793100 - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections N/A
Recruiting NCT02405741 - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A

External Links